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ABSTRACT (230 WORDS) 34 
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer (PCa) 35 
arising mostly from adenocarcinoma via NE transdifferentiation following androgen 36 
deprivation therapy. Mechanisms contributing to both NEPC development and its 37 
aggressiveness remain elusive. In light of the fact that hyperchromatic nuclei are a 38 
distinguishing histopathological feature of NEPC, we utilized transcriptomic analyses of our 39 
patient-derived xenograft (PDX) models, multiple clinical cohorts, and genetically engineered 40 
mouse models to identify 36 heterochromatin-related genes that are significantly enriched in 41 
NEPC. Longitudinal analysis using our unique, first-in-field PDX model of adenocarcinoma-42 
to-NEPC transdifferentiation revealed that, among those 36 heterochromatin-related genes, 43 
heterochromatin protein 1α (HP1α) expression increased early and steadily during NEPC 44 
development and remained elevated in the developed NEPC tumor. Its elevated expression 45 
was further confirmed in multiple PDX and clinical NEPC samples. HP1α knockdown in the 46 
NCI-H660 NEPC cell line inhibited proliferation, ablated colony formation, and induced 47 
apoptotic cell death, ultimately leading to tumor growth arrest. Its ectopic expression 48 
significantly promoted NE transdifferentiation in adenocarcinoma cells subjected to androgen 49 
deprivation treatment. Mechanistically, HP1α reduced expression of androgen receptor (AR) 50 
and RE1 silencing transcription factor (REST) and enriched the repressive trimethylated 51 
histone H3 at Lys9 (H3K9me3) mark on their respective gene promoters. These 52 
observations indicate a novel mechanism underlying NEPC development mediated by 53 
abnormally expressed heterochromatin genes, with HP1α as an early functional mediator 54 
and a potential therapeutic target for NEPC prevention and management.  55 
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Statement of Significance 56 
Heterochromatin proteins play a fundamental role in neuroendocrine prostate cancer, 57 
illuminating new therapeutic targets for this aggressive disease.  58 
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INTRODUCTION 59 
Neuroendocrine prostate cancer (NEPC) has become a clinical challenge in the 60 
management of castration resistant prostate cancer (CRPC). While de novo cases are rare, 61 
NEPC as a special subtype of CRPC (~10-20%) is thought to occur via NE 62 
transdifferentiation of prostate adenocarcinomas in response to androgen deprivation 63 
treatment (ADT), resisting dependence on AR signaling as an adaptive response. As next-64 
generation AR pathway inhibitors (ARPI) such as enzalutamide and abiraterone have made 65 
substantial improvements in managing CRPC adenocarcinomas in recent years (1), it is 66 
expected that the incidence of NEPC will further increase (2). Unfortunately, the overall 67 
median survival of NEPC with small cell feature is less than one year, primarily due to its 68 
aggressiveness and limited available treatment options (3). As such, a better understanding 69 
of the mechanisms underlying NEPC development remains much needed in order to 70 
develop more effective therapeutics. 71 
One distinct histopathological feature of NEPC cells is the frequent manifestation of 72 
hyperchromatic nuclei with finely dispersed chromatin and inconspicuous nucleoli, a 73 
phenomenon known as “salt and pepper” chromatin (3,4). This is in contrast to prostatic 74 
adenocarcinoma cells, which tend to have enlarged nuclei with prominent nucleoli (3,4). This 75 
special hematoxylin-staining characteristic suggests a distinct NEPC heterochromatin 76 
pattern (5). Heterochromatin is a condensed and transcriptionally inert chromosome 77 
conformation, regulated epigenetically by precise and dedicated machineries (6,7). Multiple 78 
studies have demonstrated that epigenetic regulation is one major mechanism underlying 79 
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NEPC development (8-11). An NEPC-specific heterochromatin gene signature can thus 80 
shed light to help better understand the disease and identify novel therapeutic targets. 81 
Another distinct feature of NEPC is the lineage alteration associated with a decrease or loss 82 
of crucial adenocarcinoma lineage-specific transcription factors, AR, FOXA1 and REST (12-83 
15). This leads to the repression of AR-regulated genes (e.g. prostate-specific antigen (PSA)) 84 
and gain of neuroendocrine markers (e.g. neural cell adhesion molecule 1 (NCAM1/CD56), 85 
neuronal-specific enolase (NSE), chromogranin A (CHGA), and synaptophysin (SYP)) (12-86 
14). While recent studies have reported that EZH2 inhibits AR expression and SRRM4 87 
mediates REST splicing (8,16), the mechanisms underlying the constant transcriptional 88 
suppression of AR and REST are still not well understood. 89 
One of the major hurdles in studying NEPC is the lack of clinically relevant models, 90 
but substantial progress has been achieved recently in modeling NEPC development. 91 
Employing genetically engineered mouse (GEM) models, ectopic gain of N-myc and 92 
concomitant loss of Rb1 and Tp53 have both been demonstrated to induce de novo NEPC-93 
like tumors (8,11). Potent ADT using abiraterone in Tp53/Pten double deficient mice also 94 
promoted overt NE transdifferentiation of luminal adenocarcinoma cells (17). Employing 95 
engineered human primary cells or cell lines, N-myc, SOX2, BRN2, and SRRM4 96 
overexpression have all been shown to promote NE transdifferentiation (16,18-20). Our 97 
laboratory has established over 45 high-fidelity patient-derived xenograft (PDX) models of 98 
PCa including 5 NEPCs (www.livingtumorlab.ca) (21). Among them, LTL331/331R is the first-99 
in-field and unique PDX model of adenocarcinoma-to-NEPC transdifferentiation. Upon host 100 
castration, the primary adenocarcinoma (LTL331) initially regresses but relapses within few 101 
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months as typical NEPC (LTL331R) (21). Importantly, the whole transdifferentiation process 102 
observed in the LTL331/331R model is predictive of disease progression and is fully 103 
recapitulated in the donor patient (22), suggesting a strong clinical relevance. Because an 104 
overwhelming majority of expressed genes accounting for the NE phenotype in terminal 105 
NEPC may obscure the real drivers of disease progression required at earlier stages, we 106 
focused on identifying the early changes induced by ADT before NEPC is fully developed, 107 
with an additional secondary criterion that these changes persist into terminal NEPC. To this 108 
end, we developed a time series of the LTL331 model, for which samples were harvested at 109 
multiple points during the transition period following host castration in order to monitor the 110 
entire transdifferentiation process and discover potential drivers with early expression 111 
changes (22).  112 
In this study, we identified a heterochromatin molecular signature that is commonly 113 
upregulated in NEPC. Among the signature genes, we discovered that the upregulation of 114 
HP1α (encoded by CBX5), a gene prominently associated with constitutive heterochromatin 115 
and mediating concomitant gene silencing, was an early event in our LTL331/331R NE 116 
transdifferentiation model. HP1α expression was increased within weeks following castration 117 
but before emergence of NE genes, gradually reaching its highest level in terminally 118 
developed NEPC. HP1α is also widely expressed in clinical samples of NEPC. We show that 119 
HP1α is essential for NEPC cell proliferation, survival, and tumor growth, and its elevated 120 
expression promotes ADT-driven NE-differentiation in prostatic adenocarcinoma cells. HP1α 121 
ectopic expression reduces expression of AR and REST, two crucial transcription factors 122 
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silenced in NEPC, and enriches the repressive histone mark H3K9me3 on their respective 123 
gene promoters.   124 
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MATERIAL AND METHODS 125 
Patient-derived xenografts and clinical datasets 126 
All PDX tumor lines were grafted in NSG mice as previously described (21). This 127 
study followed the ethical guidelines stated in Declaration of Helsinki, specimens were 128 
obtained from patients with their informed written consent form following a protocol (#H09-129 
01628) approved by the Institutional Review Board of the University of British Columbia 130 
(UBC). Animal studies under the protocol # A17-0165 were approved by UBC Animal Care 131 
and Use Committee. The LTL331 castrated tissues and the NEPC-relapsed LTL331R 132 
tissues were harvested at different time points after host castration (22). Transcriptomic 133 
analysis for all PDX tumors, with the exception of the LTL331-331R castration time-series 134 
samples, was performed using GE 8x60K microarray, as previously described (21). 135 
Transcriptomic analysis of the LTL331-331R time-series was done using RNA-sequencing 136 
data.  137 
The clinical cohorts used in this study are as follows: RNA-seq data for the Beltran et 138 
al. 2011 cohort (30 adenocarcinomas, 6 NEPCs) was from Weill Medical College of Cornell 139 
University (23); RNA-Seq data for the Beltran et al. 2016 (34 CRPC-adenocarcinomas, 15 140 
NEPCs) the Grasso et al. 2012 (31 CRPC-adenocarcinomas, 4 NEPCs), and the Kumar et 141 
al. 2016 (149 CRPC-adenocarcinomas) cohorts were accessed through the cBioPortal 142 
(10,24-26); microarray data for the Varambally et al. 2015  cohort (6 CRPC-143 
adenocarcinomas) was accessed from the Gene Expression Omnibus (GEO) database 144 
(GSE3325) (27).    145 
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 146 
Human prostate cancer specimens 147 
PCa specimens were obtained from the Vancouver Prostate Centre Tissue Bank 148 
(103 hormone naive primary prostatic adenocarcinomas, 120 CRPC-adenocarcinomas, 8 149 
NEPCs). This study followed the ethical guidelines stated in Declaration of Helsinki, 150 
specimens were obtained from patients with their informed written consent form following a 151 
protocol (#H09-01628) approved by the Institutional Review Board of the University of British 152 
Columbia (UBC). Tissue microarrays of duplicate 1 mm cores were constructed manually 153 
(Beecher Instruments, MD, USA). NEPC specimens are histologically either small cell 154 
carcinoma or large cell neuroendocrine carcinoma with low or negative AR expression and 155 
positive CHGA expression as determined by IHC staining.  156 
  157 
Cell line culture and reagents 158 
NCI-H660 and 293T cells were obtained from ATCC. Cells were authenticated with 159 
fingerprinting method at Fred Hutchinson Cancer Research Centre (Seattle, USA). 160 
Mycoplasma testing was routinely performed at the Vancouver Prostate Centre.  NCI-H660 161 
cells was cultured in RPMI-1640 medium (Hyclone) with supplements as follows: 5% FBS 162 
(GIBCO), 10 nM beta-estradiol (Sigma), 10 nM Hydrocortisone (Sigma), 1% Insulin-163 
Transferrin-Selenium (Thermo Fisher). V16D (20) cells were maintained in RPMI-1640 164 
containing 10% FBS. 293T was kept in DMEM (Hyclone) with 5% FBS. For in vitro NE 165 
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phenotype induction in V16D cells, cells were starved with phenol-red free RPMI-1640 166 
(GIBCO) containing 10% Charcoal-Stripped Serum (CSS) (GIBCO) for 24 hours, then 167 
cultured in the same media or with the addition of 10 μM enzalutamide (Haoyuan 168 
Chemexpress) for another 14 days (20).  169 
 170 
Bioinformatics analysis 171 
As previously described, Gene Set Enrichment Analysis (GSEA) 172 
(http://software.broadinstitute.org/gsea/index.jsp) was used in this study to determine 173 
whether a defined set of genes show significant, concordant differences between two 174 
biological phenotypes (e.g. PCa adenocarcinoma vs. NEPC) or two sample groups (e.g. shC 175 
vs. KD) (28). All GSEA analyses in this study used whole transcriptomic data without 176 
expression level cut-off as expression datasets. Normalized values were used for profiling 177 
data from PDX tissues, H660 and V16D stable cell lines, and the three NEPC mouse models 178 
(GSE90891, GSE92721, GSE86532); raw read numbers was used for RNA-seq data from 179 
the Beltran et al. 2011 cohort; pre-ranked gene list based on p-value from lowest to highest 180 
was used for the Beltran et al. 2016 cohort (8,10,11,17,21,23). Unbiased analysis was 181 
performed using the latest MSigDB database for each collection (29). Phenotype 182 
permutation was applied when the sample size grouped in one phenotype was more than 183 
five. Otherwise, gene set permutation was employed. False discovery rate (FDR) q values 184 
were calculated using 1000 permutations, a geneset was considered significantly enriched if 185 
its normalized enrichment score (NES) has an FDR q below 0.25.  186 
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Ingenuity pathway analysis (IPA) was performed as previously described (20). 187 
Differentially expressed genes were selected based on the criteria that their standard 188 
deviation between samples of one group (e.g. three HP1α knockdown lines) is below 0.5 189 
and their student’s t-test p-value between groups (e.g. shC vs. KD) is below 0.05.  190 
For the NE scores and the heterochromatin score, the weight for each gene in the 191 
score list was first calculated by taking the log2 of the p-value of all genes and multiplying it 192 
by the sign of the fold change. The weight for each gene in Lee et al. 2016 was obtained 193 
directly from their study. The p-values for the genes contributing to heterochromatin score 194 
was calculated by comparing NEPC PDXs with all other adenocarcinoma PDXs with the 195 
Student’s t-test. A score was then assigned to each sample by multiplying the weight with 196 
the normalized RNA expression value, adding all values for each gene, log-transforming the 197 
absolute value of the sum value, and multiplying the sign of the sum value (10,11,18).  198 
The heatmap was constructed using the Gplots and heatmap.2 packages in R. 199 
Hierarchal clustering was used to determine sample similarity.  200 
 201 
Statistical analysis and data representation 202 
Statistical analysis was done using the Graphpad Prism software. The Student’s t-203 
test was used to analyze statistical significance between groups in discrete measurements 204 
while two-way ANOVA was used for continuous measurements. The Kaplan-Meier method 205 
was used to estimate curves for relapse-free survival, and comparisons were made using 206 
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the log-rank test. Pearson correlation (with 95% confidence intervals) was used to measure 207 
the linear correlation between two variables. Any differences with p-values lower than 0.05 is 208 
regarded as statistically significant, with *p<0.05, **p<0.01, ***p<0.001. Graphs show pooled 209 
data with error bars representing standard error of the mean (SEM) obtained from at least 210 
three replicates and standard deviation (SD) of values from clinical samples. Lines in scatter 211 
plots represent the median value of measurements from multiple samples and mean with 95% 212 
confidence interval (CI) for scores from multiple samples. Box plot with whiskers showing 5-213 
95% percentile values was used to represent analysis of IHC scores.  214 
 215 
Accession numbers 216 
All PDX microarray profiles are available at www.livingtumorlab.ca, and accessible under the 217 
accession number GSE41193 in the GEO database. RNA-seq profiles for the LTL331/331R 218 
castration time-series have been deposited to the European Nucleotide Archive and are 219 
available under the accession number ENA: PRJEB9660. Microarray profiles for cell lines 220 
are deposited (GSE105033).  221 
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RESULTS 222 
NEPC has a distinctive heterochromatin gene signature  223 
To determine if a specific gene expression program contributes to the 224 
hyperchromatic histological feature of NEPC cells, we first performed an unbiased gene set 225 
enrichment analysis (GSEA) using our latest PDX collection and two NEPC clinical cohorts. 226 
Transcriptomic profiles from our high-fidelity PDX models (18 adenocarcinomas vs. 4 227 
NEPCs), the Beltran, et al. 2011 cohort (30 adenocarcinomas vs. 6 NEPCs), and the Beltran, 228 
et al. 2016 cohort (34 CRPC-adenocarcinomas vs. 15 NEPCs) (10,21,23) all demonstrate 229 
that heterochromatin-associated genes are significantly enriched in NEPC compared to 230 
adenocarcinoma (Fig. 1A-1C, S1A). We further analyzed three GEM models mimicking the 231 
development of NEPC. Interestingly, heterochromatin-associated genes are also significantly 232 
enriched as long as NE differentiation occurs, driven by either Pten/Rb double knockout 233 
(DKO) or Pten/Rb/Tp53 triple knockout (TKO), Pten/Tp53 knockout with potent ADT, or N-234 
Myc overexpression (Fig. 1D-1F) (8,11,17).  235 
To further decipher the genes contributing to the heterochromatin feature of NEPC, 236 
we analyzed the leading edge genes derived from the GSEA of PDX and clinical NEPC 237 
samples (Fig. 1A-1C). Since the NEPCs in our PDX collection are all typical neuroendocrine 238 
carcinomas without mixed adenocarcinoma tissues, the upregulated genes identified in the 239 
NEPC PDXs and validated in the clinical cohorts can be considered heterochromatin 240 
signature genes. In addition, three polycomb-group (PcG) genes, EZH2, RBBP4 and RBBP7, 241 
are also included in this gene signature as their upregulated expression in NEPC have been 242 
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previously reported (9,23). They have also been reported to play important roles in 243 
heterochromatin formation (7), but are omitted from the GSEA geneset (GO:0000792) 244 
containing other PcG members. As such, 36 genes were identified and selected to form a 245 
heterochromatin gene panel, which could successfully distinguish NEPC from 246 
adenocarcinoma through hierarchical clustering similar to two reported NE score gene 247 
panels (Fig. 1G, S1B-S1E) (10,18). From this heterochromatin gene panel, a weighted score 248 
was calculated for each sample in the PDX and clinical cohorts following a similar strategy 249 
utilized in recent studies (10,11,18). Notably, similar to NEPC samples having a distinctly 250 
higher NE score compared to adenocarcinomas, NEPC samples also have a significantly 251 
higher heterochromatin score compared to adenocarcinoma (Fig. 1H). Importantly, the 252 
heterogeneity among PDX samples is much smaller than that observed in any clinical 253 
cohorts regardless of the scoring system employed, further demonstrating that our PDX 254 
collection both clearly reflects the clinical features of NEPC and adenocarcinoma and 255 
provide a distinct system to study PCa subtypes. Together, these analyses indicate that a 256 
heterochromatin-related gene expression signature is a unique feature of NEPC tumors. 257 
 258 
Expression of heterochromatin protein 1α (HP1α) is upregulated early and steadily 259 
during NEPC development  260 
Inspired by the critical functional role of heterochromatin structure in modulating cell 261 
behavior and gene expression (6,7), we hypothesized that these NEPC-specific 262 
heterochromatin signature genes could contribute to NEPC development. As such, we 263 
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attempted to identify a potential NEPC driver gene from our 36 heterochromatin signature 264 
genes. In addition to a final upregulation in terminal NEPC, expression of the candidate 265 
driver gene would also be increased early prior to full NEPC development. We thus analyzed 266 
the RNA-seq profile of the LTL331/331R NE-transdifferentiation model with samples from 267 
castration-induced dormant time points prior to full NEPC relapse (21,22). Ranked by the 268 
gene expression difference between pre- and post-castration samples, elevated expression 269 
of HP1α was found to be an early and dramatic event occurring upon host castration. 270 
Conversely, expression of other genes that have been reported to be associated with NEPC 271 
such as EZH2 and CBX2 (9,23) were only upregulated in the fully developed NEPC sample 272 
(LTL331R) (Fig. 2A). Interestingly, we also noticed that Hp1α expression gradually increased 273 
as the NE phenotype progressed from partial to more dominantly overt in the Pten/Tp53 274 
CRPC mouse model (Fig. S2A), lending further support that elevated HP1α expression is an 275 
early event in NEPC development. 276 
To validate our findings, we performed quantitative RT-PCR (qRT-PCR) to detect 277 
HP1α expression at the mRNA level and IHC staining and Western blotting to detect HP1α 278 
expression at the protein level in our PDX collection. Both the mRNA and protein levels of 279 
HP1α are significantly increased in NEPC PDXs (Fig. 2B-2D, S2B). Furthermore, we 280 
confirmed HP1α expression in the LTL331/331R castration time-series samples. Consistent 281 
with the RNA-seq data, both the mRNA and protein expression of HP1α increased upon host 282 
castration, with increased mRNA observed as early as 1 week post-castration and elevated 283 
protein expression observed 3 weeks post-castration (Fig. 2E-2G). Taken together, these 284 
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data demonstrate that elevated expression of HP1α is an early and consistent event 285 
throughout NEPC development and could be a potential driver of NEPC. 286 
 287 
HP1α expression is upregulated in clinical NEPC samples and correlates with poor 288 
prognosis  289 
To determine the clinical relevance of elevated HP1α expression in NEPC, we 290 
analyzed RNA expression profiles from three individual clinical cohorts containing NEPC 291 
samples. In the Beltran et al. 2011 cohort, HP1α expression was about 4 times higher in 292 
NEPCs (n=6) compared to adenocarcinomas (n=30) (Fig. 3A) (23). In the Beltran et al. 2016 293 
cohort, HP1α expression was also significantly upregulated in NEPCs (n=15) compared to 294 
CRPC adenocarcinoma samples (n=34) by around two folds (Fig. 3B) (10). In another cohort 295 
consisting of 35 metastatic CRPC samples, 4 samples with NEPC features expressed 296 
significantly higher HP1α mRNA than other typical adenocarcinomas (Fig. 3C) (24). To 297 
better understand the relationship between HP1α expression and the NEPC phenotype at a 298 
protein level, we performed IHC for HP1α with the Vancouver Prostate Centre (VPC) clinical 299 
PCa tissue microarrays (TMAs) containing 103 primary adenocarcinomas, 120 CRPC 300 
adenocarcinomas and 8 typical NEPC samples. Consistent with its mRNA level, HP1α 301 
protein was significantly overexpressed in NEPCs (mean=2.45) compared to primary 302 
adenocarcinomas (mean=1.66, p=0.011) and CRPC adenocarcinomas (mean=1.60, 303 
p=0.014) (Fig. 3D, 3E). These data together demonstrate that HP1α is highly expressed in 304 
NEPC. 305 
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While HP1α is dramatically upregulated in NEPC, we also noticed that some 306 
adenocarcinomas also expressed higher levels of HP1α than others (Fig. 3D). We then 307 
investigated whether the expression of HP1α is associated with poor patient prognosis, thus 308 
possibly being a pre-disposing factor to poor outcome. Among the 103 primary 309 
adenocarcinoma samples in the VPC cohort, there were 37 samples with clinical follow-up 310 
information. Kaplan-Meier analysis showed that patients with high expression of HP1α (IHC 311 
score>=2) had a significantly shorter disease-free survival time (HR=4.627, p=0.0074) than 312 
low HP1α-expressing patients (IHC score <2) (Fig. 3F). For CRPC patients, the group with 313 
high expression of HP1α (top 1/3) had a significantly shorter overall survival time after the 314 
first hormonal therapy (HR=2.961, p=0.021), implying that HP1α positively correlates with 315 
poor prognosis upon hormonal therapy (Fig. 3G). Overall, these analyses indicate that 316 
increased expression of HP1α is a poor prognostic factor in advanced PCa.  317 
 318 
HP1α knockdown inhibits NEPC cell proliferation and induces apoptosis, leading to 319 
tumor growth arrest 320 
Considering that HP1α is significantly upregulated in NEPC, we proceeded to 321 
investigate its function in NEPC cells. NCI-H660 is a unique and typical NEPC cell line (30). 322 
Consistent with the high HP1α expression observed in clinical NEPC samples, HP1α is also 323 
expressed at the highest level in H660 cells compared to seven other PCa cell lines at both 324 
RNA and protein levels (Fig. S3A). We thus constructed stable H660 cell lines with HP1α 325 
knocked down using lentiviral-delivered shRNAs (Fig. 4A). Upon HP1α knockdown, the 326 
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overall proliferation of H660 cells was significantly inhibited, as evaluated by both crystal 327 
violet staining and cell counting (Fig. 4B, S3B). We further performed colony formation 328 
assays to evaluate the reproductive and survival ability of single cells. Remarkably, HP1α 329 
knockdown was able to ablate the colony formation ability of H660 cells (Fig. 4C). We then 330 
proceeded to analyze in greater detail the potential cellular mechanisms underlying the 331 
attenuation of cell growth mediated by HP1α knockdown. An EdU incorporation assay 332 
showed that knockdown of HP1α led to a significant reduction of EdU-positive, DNA 333 
synthesis-active cells (Fig. 4D). Furthermore, an apoptosis assay and FACS analysis 334 
indicated that HP1α knockdown also promoted cell early-apoptosis and final death (Fig. 4E, 335 
4F). Molecularly, the apoptosis markers cleaved-caspase 3 and cleaved-PARP1 were both 336 
upregulated in knockdown cells (Fig. 4G); multiple machineries involved in DNA damage 337 
repair and cell cycle progression were also impaired in HP1α knockdown cells as 338 
determined by GSEA and ingenuity pathway analysis (IPA) from stable cell line 339 
transcriptomic profiles (Fig. 4H, S3C, S3D). Thus, HP1α depletion inhibited NEPC cell 340 
proliferation and induced apoptosis in vitro.  341 
We then assessed the functional impact of HP1α knockdown on tumor growth in vivo. 342 
Compared to control H660 cells, xenograft tumor growth of the KD2 stable cell line with 70% 343 
HP1α knockdown (Fig. 4A, S3E) was observed to be dramatically inhibited and much slower, 344 
as determined by continuous tumor volume measurements and final fresh tumor weights 345 
(Fig. 4I, 4J). The other two stable lines (KD1, KD3) with 80%~95% HP1α knockdown were 346 
not able to generate sufficient cell numbers for in vivo tumor formation assays. Taken 347 
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together, the in vitro and in vivo studies establish that HP1α knockdown could both inhibit 348 
NEPC cell proliferation and induce apoptosis, leading to NEPC tumor growth arrest. 349 
 350 
HP1α promotes NE transdifferentiation of prostatic adenocarcinoma cells following 351 
ADT 352 
Since HP1α was identified as a potential early driver of NEPC development following 353 
hormone therapy, we further investigated whether HP1α could enhance NE phenotype in 354 
ADT-induced NE differentiation of adenocarcinoma cells similar to our LTL331/331R NE-355 
transdifferentation PDX model. We used V16D cells, a LNCaP-derived CRPC cell line (20), 356 
to construct stable cell lines with HP1α ectopic expression (Fig. 5A). Upon ADT using 357 
charcoal-stripped serum (CSS) or enzalutamide (EnZ) treatment for 14 days, both control 358 
and HP1α-overexpressing V16D cells were assessed for the expression of terminal NE 359 
markers. HP1α overexpression significantly promoted the expression of NCAM1 (CD56) and 360 
NSE, as shown by both qRT-PCR and Western blotting (Fig. 5B, 5C). HP1α overexpression 361 
alone was not able to induce NE transdifferentiation (Fig. 5B, 5C). Further transcriptomic 362 
analysis of control and HP1α-overexpressing V16D cells upon EnZ treatment revealed that 363 
HP1α overexpression consistently upregulated the expression of a panel of NEPC marker 364 
genes and enriched neuronal-associated signaling pathways (Fig. 5D, 5E, S4A). Pearson 365 
correlation analyses with transcriptomic data from multiple CRPC clinical cohorts (i.e., the 366 
Beltran et al. 2016, the Kumar et al. 2016, the Grasso et al. 2012, and the Varabally et al. 367 
2005) further demonstrated that high expression of HP1α is positively correlated with the 368 
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expression of terminal NE markers (i.e., NCAM1, NSE, CHGA, CHGB) in advanced PCa 369 
(10,24,25,27) (Fig. 5F, 5G, S4B, S4C). Overall, these analyses suggest that HP1α is a 370 
potential functional driver promoting NE transdifferentiation. 371 
 372 
HP1α represses AR and REST expression and enriches H3K9me3 on their promoters 373 
We further analyzed how HP1α contributed to the NE phenotype. A major function of 374 
HP1α in heterochromatin is to repress gene expression using epigenetic machineries 375 
(31,32), which is an observation supported by our transcriptomic analyses with HP1α 376 
knockdown and overexpressing cells (Fig. 5E, S4D). Decreased or loss of expression of the 377 
crucial adenocarcinoma lineage-specific transcription factors AR, FOXA1 and REST is a 378 
well-established mechanism leading to NE differentiation (12-14). Notably, when HP1α was 379 
overexpressed in V16D cells, AR and REST were downregulated at both the mRNA and 380 
protein levels (Fig. 6A, 6B, S5A). Consistently, a panel of AR target genes that are 381 
repressed in clinical NEPCs are also downregulated upon HP1α overexpression in V16D 382 
cells (Fig. 6C). Reciprocally, HP1α knockdown in H660 cells reactivated AR and REST 383 
mRNA expression (Fig. S5B), though their protein levels remained undetectable due to low 384 
abundance.  385 
We next investigated potential mechanisms underlying the downregulation of AR and 386 
REST upon HP1α overexpression. We found that, rather than affecting global 387 
heterochromatin related genes, HP1α overexpression significantly enriched (while 388 
knockdown impaired) pericentric heterochromatin machineries as determined by GSEA 389 
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(Fig.6D, S5C-S5E). Pericentric heterochromatin is a constitutive heterochromatin structure 390 
characterized by the repressive histone mark H3K9me3 (32). We then performed a 391 
chromatin immunoprecipitation (ChIP) assay to examine the occupancy of H3K9me3 on the 392 
promoter regions of AR and REST following HP1α modulation. Interestingly, in V16D cells, 393 
HP1α overexpression increased the occupancy of H3K9me3 on both the AR and REST 394 
promoters, while its knockdown in H660 cells decreased H3K9me3 enrichment on the AR 395 
promoter (Fig. 6E, S5F). In accordance with our findings in cell lines, the pericentric 396 
heterochromatin geneset is consistently and significantly enriched in NEPCs compared to 397 
adenocarcinomas in our PDX models, multiple clinical cohorts, and GEM models (Fig. 6F, 398 
S5G). Meanwhile, Pearson correlation analyses with multiple clinical cohorts showed that 399 
HP1α expression is negatively correlated with AR and REST expression in advanced PCa 400 
samples (Fig. 6G, 6H, S5H) (10,24,25,27). Overall, our data indicate that HP1α could 401 
regulate expression of the two crucial adenocarcinoma lineage-specific transcription factors 402 
AR and REST potentially via modulating the enrichment of H3K9me3 on their promoters.  403 
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DISCUSSION 404 
Loss of luminal epithelial cell characteristics together with gain of small cell 405 
neuroendocrine features makes NEPC a completely different disease than typical 406 
adenocarcinoma CRPC. This transdifferentiation makes all ARPIs inapplicable despite their 407 
otherwise remarkable revolution on the treatment of advanced PCas (1,14). More critically, 408 
the application of potent ARPIs for the clinical management of CRPC could accelerate the 409 
incidence of NEPC in near future (2,3,33). As such, deciphering the biological and molecular 410 
mechanisms underlying NEPC development is fundamentally important for developing novel 411 
therapeutics. 412 
Gross differences in nuclear hyperchromatic morphology between adenocarcinoma 413 
cells and NEPC cells have long been a criterion for NEPC pathological diagnosis. Our study 414 
here unmasks, for the first time, the precise molecular basis underlying this NEPC-specific 415 
nuclear phenotype and identifies a 36-gene NEPC heterochromatin signature using multiple 416 
high-fidelity prostatic adenocarcinoma and NEPC PDXs and two prevalent clinical cohorts. 417 
Notably, our heterochromatin gene signature can significantly distinguish NEPCs from 418 
adenocarcinomas similar to two other NEPC gene signatures derived from whole-genomic 419 
differences, suggesting a crucial function of heterochromatin in NEPC and also a potential 420 
application for diagnostic purposes. Furthermore, as epigenetic machineries play a major 421 
foundational role in heterochromatin formation and function (6,34), this 36-gene 422 
heterochromatin signature also includes 29 epigenetic factors (35). Among them, PcG genes 423 
such as EZH2 have already been demonstrated to play critical roles in NEPC (8,9,36). Thus, 424 
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these heterochromatin genes also provide a molecular basis for NEPC development and 425 
aggressiveness. Considering that the hyperchromatic nuclear pattern in NEPC is also 426 
shared by other small cell carcinomas such as small cell lung cancer (SCLC), this 427 
heterochromatin signature may be further applicable to small cell carcinomas of other tissue 428 
origins (37). 429 
From these 36 heterochromatin genes, HP1α was identified as a potential early 430 
driver of NE transdifferentiation. The longitudinal analyses of LTL331 PDX tissues following 431 
host castration demonstrated that the upregulated expression of HP1α is an early event. 432 
This is in contrast to a number of genes previously reported to be involved in NEPC 433 
development, such as EZH2, CBX2 (9,23), which were only upregulated in the fully 434 
developed NEPC LTL331R tumor. Notably, our LTL331/331R model is not only clinically 435 
relevant (21,22), but also highly reproducible in delivering the same NE transdifferentiation in 436 
18 individual repeats without exception so long as castration is applied. This robust 437 
phenomenon indicates that NE transdifferentiation in the LTL331/331R model is lineage 438 
determined, and the early changes detected in castrated tumors may thus reflect an 439 
inevitable and not stochastic event. More importantly, we indeed demonstrate that HP1α can 440 
promote terminal NE marker expression in adenocarcinoma cells following ADT. In our study, 441 
we also noticed that while HP1α was able to repress AR expression and AR signaling under 442 
AR-driven prostatic epithelial status, it cannot function as a neural factors to directly induce 443 
the NE phenotype. Only when AR signaling is diminished by ADT can HP1α ectopic 444 
expression promote NE transdifferentiation in adenocarcinoma cells. This process both 445 
recapitulates the in vivo NE transdifferentiation phenotype occurring in the LTL331/331R 446 
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model, and also mirrors the clinical progression of NEPC where most cases appear after 447 
hormonal therapy (3,33). In terminal NEPC cells where HP1α mainly functions as a regulator 448 
of aggressiveness, HP1α knockdown cannot alter NE phenotype (Fig. S6A). Therefore, 449 
HP1α could potentially serve as an early therapeutic target to interfere with disease 450 
progression before NEPC fully develops.  451 
In addition to being significantly overexpressed in clinical NEPC samples, HP1α 452 
plays a crucial role in terminal NEPC as demonstrated by thorough functional studies in the 453 
bona fide NEPC cell line NCI-H660. While previous studies have reported the function of 454 
HP1α in breast cancer, lung cancer, and cholangiocarcinoma, its function in prostate cancer 455 
remains elusive (38-42). Our data demonstrates that HP1α knockdown in NEPC cells 456 
dramatically inhibited proliferation, completely ablated colony formation, and induced 457 
apoptotic cell death. Consequently, HP1α depletion markedly inhibited NEPC tumor growth 458 
in vivo. Alternatively, in V16D adenocarcinoma cells where HP1α overexpression promoted 459 
NE transdifferentiation, HP1α overexpression did not significantly enhance proliferation (Fig. 460 
S6B). These data suggests that HP1α is particularly essential for NEPC malignancy, with 461 
one potential mechanism being HP1α depletion impairs mitotic machineries. While reported 462 
to drive and maintain heterochromatin structure (31,32,43), HP1α is prominently associated 463 
with constitutive heterochromatins (44) as demonstrated through our study. Depletion of 464 
HP1α did not affect heterochromatin-related genes universally, but significantly impaired the 465 
pericentric constitutive heterochromatin machineries. Pericentric heterochromatin is a key 466 
element ensuring proper chromosome segregation in metaphase (6), which is also a major 467 
previously reported function of HP1α (38,45). The abnormally enriched pericentric 468 
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heterochromatin genes in NEPCs may also explain the highly proliferative feature of NEPC, 469 
for which HP1α may play a driver function. Another potential mechanism underlying the 470 
essential function of HP1α in NEPC aggressiveness is that HP1α depletion impaired DNA 471 
damage response (DDR) machineries, which is in accordance with previous studies (46,47). 472 
Most recently, another study also reported that a DDR pathway is enriched in NEPC, 473 
contributing to NEPC cell proliferation (48). Overall, HP1α could potentially serve as a 474 
therapeutic target for effective management of developed NEPC.  475 
Our findings also suggest a novel, HP1α-mediated mechanism of NEPC 476 
development. AR, FOXA1 and REST are the three crucial adenocarcinoma lineage-specific 477 
transcription factors maintaining luminal epithelial characteristics (12-14). Our data 478 
demonstrates that HP1α can repress AR and REST expression in adenocarcinoma cells, 479 
while its depletion in NEPC cell can reactivate their expression. HP1α gene was first 480 
identified to be a modulator of position effect variegation where euchromatic genes 481 
abnormally juxtaposed with pericentric heterochromatin could be silenced due to compaction 482 
into heterochromatin (49). In our study, we also found that HP1α may play an epistatic role 483 
in regulating the pericentric heterochromatin apparatus. The repressive histone mark 484 
H3K9me3 is a hallmark of pericentric heterochromatin and also a major substrate 485 
recognized by HP1α (31,32). Given that the AR and REST genes are natively located in the 486 
vicinity of pericentric heterochromatins (Xq12 and 4q12 respectively, Fig. S6C), they could 487 
potentially be sensitive to pericentric heterochromatin deregulation. Our data indeed showed 488 
that modulation of HP1α regulates the enrichment of H3K9me3 on the promoters of AR and 489 
REST. Considering the significant enrichment of H3K9me3-characterized pericentric 490 
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heterochromatin genes in multiple NEPC models and clinical cohorts, our study suggests 491 
that the HP1α/H3K9me3 axis may partially explain the absence or loss of AR and REST 492 
expression in NEPCs. Further investigation on genome-wide occupancy of HP1α and 493 
H3K9me3 will provide valuable insights. HP1α mediates gene silencing together with other 494 
precise epigenetic machineries (31). Previous studies have shown that AR expression can 495 
also be repressed by the EZH2/H3K27me3 axis (8,36). As such, HP1α/H3K9me3 might 496 
coordinate with EZH2/H3K27me3, establishing the complete repression of AR in NEPCs. 497 
Alternative splicing has been suggested to suppress REST in NEPCs (16). HP1α was also 498 
reported to mediate mRNA alternative splicing and exon recognition (50). As such, HP1α 499 
might be involved in mediating REST splicing as well. Our data here suggests 500 
HP1α/H3K9me3 as a new mechanism leading to the silencing of REST mRNA in most 501 
NEPC samples.  502 
In summary, our data imply a novel mechanism underlying NEPC development: 503 
HP1α drives the abnormal formation of pericentric heterochromatin, which in turn promotes 504 
ADT-induced NE transdifferentiation via repressing AR and REST expression, and confers 505 
the malignant NEPC phenotype via promoting aggressive proliferation and cell survival. 506 
Taken together HP1α can be considered an early and master mediator of NEPC 507 
development and aggressiveness, making it an exceptional novel therapeutic target for 508 
potentially effective treatment of NEPC.   509 
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FIGURE LEGENDS 674 
Figure 1. NEPC has a distinctive heterochromatin gene signature. (A-F) GSEA show the 675 
enrichment of heterochromatin-associated genes in NEPC from (A) PDX models, (B) the 676 
Beltran et al. 2011 cohort (23), (C) the Beltran et al. 2016 cohort (10), and in NE-like GEM 677 
models derived from (D) Rb/Tp53 DKO or Pten/Rb/Tp53 TKO (11), (E) NPp53 CRPC with 678 
NE differentiation (17), (F) and Nmyc overexpression (8). “NES” stands for normalized 679 
enrichment score; FDR q values were calculated using 1000 gene permutations except for 680 
(C), where Gsea preranked was applied. (G) Heatmap showing the hierarchical clustering 681 
among all PDX samples suggests a unique upregulation of heterochromatin signature genes 682 
in NEPC PDX tumors. (H) Weighted NE scores and heterochromatin scores of 683 
adenocarcinoma and NEPC PDX tumors and two clinical cohorts. NE scores were 684 
calculated based on the gene panels from Beltran et al. 2016 (10) and Lee et al. 2016 (18). 685 
Heterochromatin scores were calculated based on the weighted gene panel from (G). 686 
Scatter plots show the calculated score of each tumor sample, with lines indicating the mean 687 
value and 95% CI. The p-values were calculated using the unpaired two-tail Student’s t-test. 688 
See also Fig. S1. 689 
Figure 2. HP1α expression is upregulated during NE transdifferentiation and in NEPC 690 
PDX models. (A) A heatmap showing the gene expression changes in the LTL331/331R NE 691 
transdifferentiation PDX model. Heterochromatin signature genes, AR signaling targets, and 692 
NE markers are included. RNA-seq data from two individual samples at each time point was 693 
used (pre: LTL331 pre-castration; Cx: 8 weeks post-castration; Rep: LTL331R NEPC 694 
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relapse). Average differences in expression between castrated and pre-castrated tumors (C 695 
vs. P) are shown in a separate heatmap. (B-D) HP1α expression in PDX models, as 696 
determined by (B) qRT-PCR, (C) IHC, and (D) Western blotting. Scatter plots show relative 697 
mRNA expression or IHC score for each sample, with lines indicating median values. (E-G) 698 
HP1α expression in the LTL331/331R castration-induced NE transdifferentiation PDX model, 699 
as determined by (E) qRT-PCR, (F) Western blotting, and (G) IHC. Data show mean ± SEM 700 
from three replicates. The p-values (B, C, E) were calculated with unpaired two-tail Student’s 701 
t-tests. See also Fig. S2.  702 
Figure 3. HP1α expression is upregulated in clinical NEPC samples and correlates 703 
with poor prognosis in adenocarcinomas. (A-C) HP1α mRNA expression in NEPC vs. 704 
adenocarcinoma from (A) the Beltran, et al. 2011 cohort (23), (B) the Beltran, et al. 2016 705 
cohort (10), and (C) the Grasso, et al. 2012 cohort (24). Scatter plots show RNA expression 706 
data of each sample, with lines indicating median values. The p-values were calculated 707 
using unpaired two-tail Student’s t-test. (D) Staining intensity for the HP1α protein in primary 708 
adenocarcinomas (n=103), CRPC-adenocarcinomas (n=120), and NEPC (n=8) as 709 
determined by IHC of the VPC TMA. Box plots show the mean with whiskers representing 5-710 
95% percentile values. The p-values were calculated using unpaired two-tail Student’s t-test. 711 
(E) Representative IHC images for the various staining intensities (0 to 3) are shown, with 712 
the lower panels being magnifications of the selected regions in the upper panels. Scale 713 
bars in the upper and lower panels represent 100 μm and 10 μm respectively. (F-G) Kaplan-714 
Meier survival analyses of estimated (F) relapse-free survival time based on the HP1α IHC 715 
score of primary adenocarcinomas from the VPC cohort with follow-up information (n=37) 716 
Research. 
on March 1, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on February 27, 2018; DOI: 10.1158/0008-5472.CAN-17-3677 
 35 
and (G) prostate-cancer specific survival time after first hormonal therapy based on HP1α 717 
mRNA from metastatic adenocarcinomas in the Grasso, et al. 2012 cohort (n=33) (24). The 718 
p-values were calculated using the log-rank test to determine the difference in outcomes 719 
between patients with high (red) and low (black) HP1α expression.  720 
Figure 4. HP1α is essential for the aggressive growth of NEPC cells and tumors. (A) 721 
Stable knockdown of HP1α in NCI-H660 cells by lentiviral transduction. Changes to HP1α 722 
mRNA and protein levels were determined by qRT-PCR and Western blotting respectively. 723 
Bar graph shows mean ± SEM. The p-value was calculated by unpaired two-tail Student’s t-724 
test. (B) Cell growth assay of HP1α knockdown H660 cells as determined by crystal violet 725 
staining. Stable cells were plated in four replicate wells for each time point and cell numbers 726 
were determined based on the absorbance at O.D. 572 nm of crystal violet dissolved in 2% 727 
SDS. Data is graphed as mean ± SEM. Representative images demonstrating cell numbers 728 
at the final time point are shown. The p-value was calculated by two-way ANOVA. (C) 729 
Colony formation assay of HP1α knockdown H660 cells as determined by crystal violet 730 
staining. Cells were plated in four replicate wells for each stable line and colony numbers 731 
were counted manually. Bar graph shows mean ± SEM. Representative images 732 
demonstrating colony numbers are shown. The p-value was calculated by unpaired two-tail 733 
Student’s t-test. (D) An EdU incorporation assay was performed by incubating stable HP1α 734 
knockdown H660 cells with 10 μM EdU for 4 hours. EdU-labeled cells (red) and total cells 735 
counterstained with DAPI (blue) were counted for at least 10 fields. Bar graph shows the 736 
mean (EdU-positive ratio) ± SEM. Representative images are shown with the scale bar 737 
representing 100μm. The p-values were calculated by unpaired two-tail Student’s t-test. (E) 738 
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An apoptosis assay measuring caspase-3 activity using the ApoLive-GloTM Multiplex 739 
Reagent. Relative apoptosis was determined by the ratio of luminescence (caspase-3 740 
activity) to fluorescence (AFC signal for viable cells). Bar graph shows mean ± SEM 741 
(normalized to shC). The p-values were calculated by unpaired two-tail Student’s t-test. (F) 742 
Cell death following stable HP1α knockdown in H660 cells was determined by flow 743 
cytometry with 7-AAD staining. 10,000 single cells were collected for analysis with dead cells 744 
being 7-AAD positive. Bar graph shows mean ± SEM (normalized to shC). The p-values 745 
were calculated by unpaired two-tail Student’s t-test. (G) Apoptosis markers cleaved-746 
caspase 3 and cleaved-PARP1 as determined by Western blotting following stable HP1α 747 
knockdown in H660 cells. Intact caspase 3 and PARP1 serve as controls. Cl stands for 748 
“cleaved”. (H) Selected gene sets enriched in HP1α- versus control- knockdown H660 cells 749 
as analyzed by GSEA. The x-axis represents normalized enrichment score (NES). FDR of all 750 
gene sets is less than 0.05 calculated by 1000 permutations. (I-J) Stable H660 cell lines shC 751 
and KD2 were each grafted into four NSG mice (eight tumors total) to assess in vivo 752 
xenograft tumor growth. (I) Tumor volume was measured starting from when palpable tumor 753 
appears to when mice were euthanized. Line graph shows mean ± SEM, with p-value 754 
calculated by two-way ANOVA. Tumor images are shown in the right panel. (J) Fresh tumors 755 
were also weighed at sample collection. Bar graph shows mean ± SEM with The p-value 756 
was calculated by unpaired two-tail Student’s t-test. See also Fig. S3.   757 
Figure 5. HP1α promotes NE transdifferentiation of prostatic adenocarcinoma cells 758 
following ADT. (A) Ectopic expression of HP1α in LNCaP-V16D cells as determined by 759 
Western blotting. (B-C) Induction of NE transdifferentiation with ADT in V16D cells stably 760 
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overexpressing HP1α. Relative mRNA and protein expression of terminal NE markers (SYP, 761 
CHGA, NSE, NCAM1) were detected by (B) qRT-PCR and (C) Western blotting in stable 762 
cells cultured in complete medium (FBS), CSS, and CSS with 10 μM EnZ 14 days. Bar 763 
graphs show mean ± SEM. The p-values were calculated by unpaired two-tail Student’s t-764 
tests comparing HP1α- to control- overexpressing cells. Relative band intensities as 765 
determined by ImageJ are indicated, with actin serving as internal control. (D) A heatmap 766 
comparing expression of NEPC marker genes in the indicated V16D cells upon EnZ 767 
treatment. The select NEPC marker genes upregulated by HP1α overexpression are 768 
similarly upregulated in clinical NEPCs in the Beltran, et al. 2011 cohort (23). (E) Top 10 769 
pathways significantly enriched in HP1α overexpressing V16D cells compared to control 770 
cells as analyzed with IPA. (F-G) Pearson correlation analysis of HP1α mRNA expression 771 
and the expression of various NE markers in advanced PCa samples. (F) Correlation with 772 
NCAM1 and NSE expression in the Beltran, et al. 2016 cohort (10), and (G) correlation with 773 
CHGB and CHGA expression in the Kumar et al. 2015 cohort (25). See also Fig. S4. 774 
Figure 6. HP1α represses AR and REST expression and enriches H3K9me3 on their 775 
promoters. (A-B) AR and REST expression in stable V16D cells overexpressing HP1α as 776 
determined by (A) qRT-PCR and (B) Western blotting. Bar graphs show mean ± SEM. The 777 
p-values were calculated by unpaired two-tail Student’s t-test. (C) A heatmap comparing 778 
expression of AR signaling genes in the indicated V16D cells. The select AR target genes 779 
downregulated by HP1α overexpression are similarly downregulated in clinical NEPCs in the 780 
Beltran, et al. 2011 cohort (23). (D) GSEA of V16D cells with stable HP1α overexpression. 781 
Expression of pericentric heterochromatin components are upregulated by HP1α 782 
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overexpression. “NES” stands for normalized enrichment score; FDR q values were 783 
calculated using 1000 gene permutations. (E) ChIP-PCR shows the enrichment of H3K9me3 784 
on the promoters of AR and REST in V16D cells with HP1α overexpression, NC is a 785 
negative control region. Bar graphs show mean ± SEM. The p-values were calculated by 786 
unpaired two-tail Student’s t-test. (F) GSEA show the enrichment of pericentric 787 
heterochromatin genes in human NEPC samples and mouse NE-like tumors. The y-axis 788 
represents normalized enrichment score (NES) and the x-axis denotes clinical cohorts and 789 
GEM models. FDR is less than 0.15 calculated by 1000 permutations. (G-H) Pearson 790 
correlation analysis of HP1α mRNA expression and AR and REST mRNA levels from (G) 791 
the Beltran et al. 2016 (10) and (H) the Kumar et al. 2016 cohorts (25). See also Fig. S5. 792 
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